Do you want to read an article? Please log in or register.
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
Gastrointestinal Cancer
Related content
Gastrointestinal Cancer
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
J Clin Oncol
Babiker HM, Picozzi V, Chandana SR, Melichar B, Kasi A, Gang J, Gallego J, Bullock A, Chunyi H, Wyrwicz L, Hitre E, Osipov A, de la Fouchardiere C, Ales I, Dragovich T, Lee W, Feeney K, Philip P, Ueno M, Van Cutsem E, Seufferlein T, Macarulla T, PANOVA-3 Study Investigators
doi: 10.1200/JCO-25-00746
Breast Cancer
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
Ann Oncol
Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, Yoshida A, Fabi A, Cao X, Joseph R, Li R, Żurawski B, Escrivá-de-Romaní S, Meneguetti R, Supavavej A, Chen SC, Liu Z, Kelly C, Curigliano G, Symmans WF, Gufran M, Ke J, Konpa A, Herbolsheimer P, Boileau JF, DESTINY-Breast11 Trial Investigators
doi: 10.1016/j.annonc.2025.10.019
Gynecologic Cancer
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
Lancet
Lorusso D, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Fagotti A, Gilbert L, Mileshkin L, Quesada S, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Clamp A, Prillaman C, Diakos C, Bagaméri A, Leiser AL, Salutari V, Monk BJ, Follana P, McClung E, Carbone V, Slomovitz B, Giudice E, Cannizzaro MC, Gavoille L, Devaux A, Scollo P, Scandurra G, Cassani C, Artioli G, Van Gorp T, Santaballa A, Dreiling LK, Kesner-Hays A, Tudor IC, Jubb AM, Colombo N, Olawaiye AB
doi: 10.1016/S0140-6736(26)00462-9
Lung, Respiratory and Thoracic Cancer
Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial
Ann Oncol
Wang C, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Zhang Z, Yao B, Wang S, Leaw S, Naicker K, Zheng W, Yu C, Yue D, RATIONALE-315 investigators
doi: 10.1016/j.annonc.2025.11.017
COMMENTED
Breast Cancer
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
★ 2
Recommended and commented by
Dr Andreas Müller, Faculty Member
J Clin Oncol
Gao HF, Ye GL, Lin Y, Huang Q, Dong J, Cao Y, Zhao YX, Chen QJ, Ma SH, Ouyang J, Ye JH, Yang HW, Zhang YQ, Zhang YC, Zhang GL, Li W, Zhang Y, Wu ZY, Lin YY, Zhu T, Zhang LL, Yang CQ, Yang M, Peng H, Chen B, Chen YT, Ji F, Cheng MY, Li JQ, Jiang Z, Wang K
doi: 10.1200/JCO-25-02176
Gastrointestinal Cancer
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma
J Clin Oncol
Ducreux M, Desgrippes R, Rinaldi Y, Di Fiore F, Guimbaud R, Evesque L, Bachet JB, Vanelslander P, Lecomte T, Capitain O, Parzy A, Bolliet M, Etienne PL, Forestier J, El Hajbi F, Bignon AL, Lebrun-Ly V, De Sousa Carvalho N, Texier M, Bouche O
doi: 10.1200/JCO-24-02210
Breast Cancer
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial
JAMA Oncol
Wang J, Zhang Q, Li H, Tong Z, Ouyang Q, Li H, Teng Y, Wang B, Sun T, Wang J, Li W, Niu Z, Li H, Gong C, Wang S, Wang X, Wu X, Liu N, Yu G, Hu Y, Wang Q, Duan X, Yang F, Wang L, Xu B
doi: 10.1001/jamaoncol.2026.0318
RECOMMENDED
Breast Cancer
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial
★ 3
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Chen X, Huang J, Shi H, Zhu J, Wu W, Ye G, He Q, Shi Y, Zhang A, Xie X, Wang X, Chen X, Wu W, Wu J, Li Z, Li Z, Dai Y, Ren W, Shao Q, Chen Y, Zeng Y, Zhang F, Dong S, Pegram MD, Shen K
doi: 10.1200/JCO-25-02412
Genitourinary Cancer
Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial
Eur Urol
Kitamura H, Tsukamoto T, Kakehi Y, Mizusawa J, Shibata T, Sasaki K, Tanikawa T, Hashine K, Fujimoto K, Masumori N, Kobayashi T, Habuchi T, Kimura T, Sugimoto M, Takahashi A, Adachi H, Matsui Y, Hatakeyama S, Ito A, Eto M, Nishiyama H, Urologic Oncology Study Group of the Japan Clinical Oncology Group
doi: 10.1016/j.eururo.2026.01.008